公开(公告)号：WO2015156674A3

公开(公告)日：2015-12-17

申请号：PCT/NL2015050237

申请日：2015-04-10

Applicant: STICHTING NL KANKER INST

Inventor： PEEPER DANIEL SIMON ,  MUELLER JUDITH NADJA

IPC: A61K31/502 ,  A61K31/437 ,  A61K31/506 ,  A61K31/519 ,  A61K35/00 ,  A61K45/06

CPC classification number: A61K31/506 ,  A61K31/437 ,  A61K31/502 ,  A61K31/519 ,  A61K45/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57496 ,  G01N2333/4706 ,  G01N2333/91205 ,  A61K2300/00

Abstract: The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to methods for treatment of these types of cancer. In particular, the disclosure relates to the combined use of an inhibitor of a protein of the MAPK/ERK pathway and an inhibitor of specific kinases in the treatment of a cancer, in particular melanoma, in a patient. In an important embodiment, the cancer is characterized by the absence or reduced expression of MITF.

Abstract translation: 本公开涉及可用于治疗某些类型的癌症的药物组合和组合物。 本公开还涉及用于治疗这些类型的癌症的方法。 具体而言，本公开涉及MAPK / ERK途径蛋白质抑制剂与特异性激酶抑制剂在患者癌症特别是黑素瘤治疗中的联合应用。 在一个重要的实施方案中，癌症的特征在于MITF的缺乏或减少的表达。